- Q1 2024 Valneva SE Earnings Call TranscriptMay 07, 2024€3.41 (-1.16%)Earnings
- Full Year 2023 Valneva SE Earnings Call TranscriptMar 20, 2024€3.37 (-10.66%)Earnings
- Valneva SE Analyst Call TranscriptNov 13, 2023
- Q3 2023 Valneva SE Earnings Call TranscriptNov 09, 2023€6.18 (+0.62%)Earnings
- Half Year 2023 Valneva SE Earnings Call TranscriptSep 21, 2023€6.04 (-4.16%)Earnings
- Valneva SE at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Valneva SE Earnings Call TranscriptMay 04, 2023€5.31 (+26.70%)Earnings
- Full Year 2022 Valneva SE Earnings Call TranscriptMar 23, 2023€4.82 (-1.63%)Earnings
- Valneva SE Corporate Analyst Meeting TranscriptDec 06, 2022
- Q3 2022 Valneva SE Earnings Call TranscriptNov 10, 2022€7 (+4.60%)Earnings
- Half Year 2022 Valneva SE Earnings Call TranscriptAug 11, 2022€9.96 (-5.14%)Earnings
- Valneva SE at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Valneva SE COVID-19 Vaccine Purchase Agreement Update TranscriptMay 16, 2022
- Q1 2022 Valneva SE Earnings Call TranscriptMay 05, 2022€11.86 (+0.13%)Earnings
- Full Year 2021 Valneva SE Earnings Call TranscriptMar 24, 2022€17.35 (+1.17%)Earnings
- Valneva SE - Special Call TranscriptOct 18, 2021
- Half Year 2021 Valneva SE Earnings Call TranscriptAug 10, 2021€3.1Earnings
- Valneva SE Annual Shareholders Meeting TranscriptJun 23, 2021
- Q1 2021 Valneva SE Earnings Call TranscriptMay 20, 2021€3.1Earnings
- Full Year 2020 Valneva SE Earnings Call TranscriptFeb 25, 2021€3.1Earnings
- Q3 2020 Valneva SE Earnings Call TranscriptNov 03, 2020€3.1Earnings
- Half Year 2020 Valneva SE Earnings Call TranscriptAug 04, 2020€3.1Earnings
- Q1 2020 Valneva SE Earnings Call TranscriptMay 07, 2020€3.1Earnings
- Full Year 2019 Valneva SE Earnings Call TranscriptFeb 27, 2020€3.1Earnings
- Nine Months 2019 Valneva SE Earnings Call TranscriptOct 31, 2019€3.1Earnings
- Half Year 2019 Valneva SE Earnings Call TranscriptAug 01, 2019€3.1Earnings
- Valneva SE R&D Investor Day Presentation TranscriptJul 09, 2019
- Valneva SE to Announce Agreement with GlaxoSmithKline PLC to End Strategic Alliance Agreement Call TranscriptJun 21, 2019
- Q1 2019 Valneva SE Earnings Call TranscriptMay 02, 2019€3.1Earnings
- Full Year 2018 Valneva SE Earnings Call TranscriptFeb 21, 2019€3.1Earnings
Valneva SE Corporate Analyst Meeting Transcript
Okay. Thanks, everyone. I think we're going to get started. Hello, and thank you for joining us for Valneva's Investor Day. I'm Josh Drumm, Vice President of Investor Relations, and it's my pleasure to welcome you this morning, as well as those listening on the webcast.
Today, you're going to hear from Valneva's management and senior leaders about the company's near and midterm value drivers, including its late-stage development pipeline, commercialized vaccines and select preclinical vaccine candidates.
In a few moments, I'll introduce CEO, Thomas Lingelbach, to provide a brief overview of Valneva in our late-stage development pipeline. Thomas will then hand it over to Katrin Dubischar, Director of our chikungunya vaccine program to provide an overview of VLA1553, including recently reported data.
Katrin will then welcome John Kanaras, General Manager of our U.S. Subsidiary to discuss the commercial outlook for our chikungunya vaccine candidate. This will be followed by a discussion from Thomas on Valneva and Pfizer's Phase III vaccine
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)